Since its emergence in US dairy cattle, highly pathogenic avian influenza (bird flu, H5N1) has defied control, spreading to other species and disrupting every stage of the dairy sector. A newly published invited review in the Journal of Dairy Science presents the most comprehensive look yet at the virus’s impact and calls for a unified response. With current science pointing to complex transmission dynamics and broad consequences, the authors argue that only a One Health approach, taking into account the intersection of animal and human health with that of the environment, can effectively combat H5N1 and prevent future outbreaks.

The American Federation for Aging Research (AFAR) has received a five-year renewal award totaling $5,722,435 from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to continue and expand the Nathan Shock Centers Coordinating Center (NSC3). The NSC3 coordinates the activities of the 8 Nathan Shock Centers (NSC) of Excellence in the Basic Biology of Aging, which provide expert resources to expand basic research into the biology of aging. 

Weill Cornell Medicine faculty member Dr. Anna Nam and postdoctoral fellow Dr. Maria Cecilia Lira have been chosen to join the 2025 class of Pew scholars and fellows.

Botulism outbreaks highlight the need for detection of food contamination at point of use. Printed on the inside of a jar lid, for example, a biosensing ink can tell the consumer if the product they are about to consume is sterile or contaminated by a simple change in color.

BUFFALO, NY — August 14, 2025 — A new research paper was published in Volume 17, Issue 7, of Aging (Aging-US) on July 3, 2025, titled “Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort.”

Cambridge, MA – Aug 14, 2025 – Insilico Medicine(“Insilico”), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has completed IND-enabling studies with favorable results. Insilico plans to submit IND application in Q4 this year, aiming to progress the candidate compound into clinical trials as a potential transformative therapy for Parkinson’s disease (PD).